Lawyers in the third Risperdal gynecomastia trial against Johnson & Johnson subsidiary Janssen Pharmaceuticals in the Philadelphia Court of Common Pleas on Thursday painted starkly different pictures to the jury on what caused a young boy to grow enlarged breasts.
Plaintiff Tim Stange’s case will be the tiebreaker in the litigation, as the first and second trials resulted in victories for the plaintiff and defendants, respectively. On Feb. 25, a jury awarded $2.5 million to plaintiff Austin Pledger, while on March 20, the jury in plaintiff William Cirba’s case came back in favor of Janssen.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
